Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Express Scripts
McKesson
Dow
Baxter

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

RHOPRESSA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Rhopressa, and what generic alternatives are available?

Rhopressa is a drug marketed by Aerie Pharms Inc and is included in one NDA. There are six patents protecting this drug.

This drug has forty-three patent family members in seven countries.

The generic ingredient in RHOPRESSA is netarsudil dimesylate. One supplier is listed for this compound. Additional details are available on the netarsudil dimesylate profile page.

Summary for RHOPRESSA
Drug patent expirations by year for RHOPRESSA
Drug Prices for RHOPRESSA

See drug prices for RHOPRESSA

Generic Entry Opportunity Date for RHOPRESSA
Generic Entry Date for RHOPRESSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RHOPRESSA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Price Vision GroupPhase 2/Phase 3
Cornea Research Foundation of AmericaPhase 2/Phase 3
Aerie PharmaceuticalsPhase 4

See all RHOPRESSA clinical trials

Pharmacology for RHOPRESSA
Drug ClassRho Kinase Inhibitor
Mechanism of ActionRho Kinase Inhibitors
Synonyms for RHOPRESSA
(4-((1S)-1-(Aminomethyl)-2-(isoquinolin-6-ylamino)-2-oxoethyl)phenyl)methyl 2,4- dimethylbenzoate
[4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate
1254032-66-0
1628418-15-4
AR 13324
AR-11324
AR-11324 free base
AR-13324
AR11324
Benzoic acid, 2,4-dimethyl-, (4-((1S)-1-(aminomethyl)-2-(6-isoquinolinylamino)-2-oxoethyl)phenyl)methyl ester
D11030
ester 60 [PMID: 27072905]
GTPL9322
Netarsudil
Netarsudil (USAN/INN)
Netarsudil [USAN:INN]
Netarsudil [USAN]
SB17091
SCHEMBL16036278
UNII-W6I5QDT7QI
W6I5QDT7QI
ZINC113149554

US Patents and Regulatory Information for RHOPRESSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Boehringer Ingelheim
Harvard Business School
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.